Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant

Wan Yang, PhD,[1*] Sharon K. Greene, PhD, MPH,[2] Eric R. Peterson, MPH,[2] Wenhui Li, PhD,[3] Robert Mathes, MPH,[2] Laura Graf, MPH,[2] Ramona Lall, PhD,[2] Scott Hughes, PhD,[4] Jade Wang, MS,[4] Anne Fine, MD[2,#]

[1]Department of Epidemiology, Mailman School of Public Health, Columbia University; [2]Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene; [3]Bureau of Vital Statistics, New York City Department of Health and Mental Hygiene; [4]Public Health Laboratory, New York City Department of Health and Mental Hygiene

*correspondence to: wy2202@cumc.columbia.edu

#current affiliation: Council of State and Territorial Epidemiologists

Abstract

Background: The B.1.526 variant (WHO designation: Iota) is a SARS-CoV-2 variant of interest, as classified by both the US CDC and the WHO. Due to a lack of extensive genomic sequencing and contact tracing data, its key epidemiological properties have not been well characterized.

Methods: We utilized nine epidemiological and population datasets collected in New York City (NYC), where B.1.526 emerged, and comprehensive modeling to estimate the changes in transmissibility, immune escape potential, and infection fatality risk (IFR) for B.1.526.

Findings: Estimated transmission rate in the neighborhood where B.1.526 was initially detected was consistently higher than other neighborhoods in NYC and further increased during the weeks preceding B.1.526 detection, likely due to its early spread there. Overall, models estimated that B.1.526 had transmissibility about 15-25% higher than previously circulating variants and that it could escape immunity in 0-10% of previously infected persons. In addition, B.1.526 substantially increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds, 82% (95% CI: 20 – 140%) among 65-74 year-olds, and 62% (95% CI: 45 – 80%) among 75+ during Nov 2020 – Apr 2021, compared to baseline IFR estimated for preexisting variants.

Interpretation: New variants like B.1.526 likely spread in the population weeks prior to detection, and partial immune escape (e.g., resistance to therapeutic antibodies) could offset prior medical advances and increase IFR. Early preparedness for and close monitoring of SARS-CoV-2 variants, their epidemiological characteristics, and disease severity are thus crucial to COVID-19 pandemic response as it remains a global public health threat.

Key words: COVID-19; variant of interest; B.1.526; transmissibility; immune escape; infection fatality risk

Research in context

Evidence before this study

We searched PubMed for studies published through June 23, 2021 on the B.1.526 (Iota) SARS-CoV-2 variant, using the terms "B.1.526", "Iota variant" and "COVID-19", or "Iota variant" and "SARS-CoV-2". Our search returned 14 papers, from which we read the abstracts and identified 8 relevant studies. The majority (7 of 8) of these studies focused on identifying the specific mutations, namely L5F, T95I, D253G, additionally E484K or S477N for two different subclades (i.e., B.1.526-S:E484K and B.1.526-S:S477N) and a closely related subclade (i.e., B.1.526-S:L452R or B.1.526.1) as defined by spike mutations D80G, Δ144, F157S, L452R, T859N, and D950H; these studies also examined changes in neutralizing ability of convalescent plasma and vaccinee sera (mild reductions by ~2-4 fold were reported) and changes in neutralizing ability of monoclonal antibodies (substantial reductions for some monoclonal antibodies were reported). Two studies used genomic data from GISAID to estimate the growth rate of B.1.526 during January - March 2021 and reported that it was similar to the Alpha variant (i.e., B.1.1.7), a SARS-CoV-2 variant of concern with around 50% higher transmissibility than preexisting variants. However, an epidemiological study using individual patient data from January 1 to April 5, 2021 reported no increases in secondary attack rate among contacts of B.1.526 cases, compared to non-VOC/VOI variants. This latter study also showed preliminary evidence that B.1.526 did not increase the risk of hospitalization or death, nor of vaccine breakthrough or reinfection.

Added value of this study

We utilized multiple datasets collected in New York City – where B.1.526 emerged – and model-inference methods to reconstruct the transmission dynamics, including the initial emergence of B.1.526 in the fall of 2020. We estimated that B.1.526 had a moderate increase (15-25%) in transmissibility and could escape immunity in 0-10% of previously infected individuals. In addition, B.1.526 substantially increased the infection-fatality risk (IFR) among adults 65 or older by >60% during Nov 2020 – Apr 2021, compared to baseline risk estimated for preexisting variants.

Implications of all the available evidence

New SARS-CoV-2 variants like B.1.526 could increase transmissibility, evade prior immunity, and increase disease severity. Early preparedness for and close monitoring of SARS-CoV-2 variants and their epidemiological characteristics are crucial to COVID-19 pandemic response as it remains a global public health threat.

INTRODUCTION

The SARS-CoV-2 virus spread quickly worldwide in early 2020, causing the COVID-19 pandemic. As the virus spread, it also diversified, and multiple novel SARS-CoV-2 variants emerged in different populations, producing both local and global waves of infection. Several variants have been characterized as variants of concern (VOC) or of interest (VOI), based on evidence regarding their ability to increase transmissibility, evade immunity conferred by either prior infection or vaccination, or cause more severe disease. Accurately estimating the epidemiological characteristics and impact of these variants is thus important for informing public health response, such as monitoring effectiveness of vaccines and therapeutic antibodies. More broadly, such findings can also provide insights into the long-term trajectory of SARS-CoV-2 beyond the pandemic phase.

The B.1.526 variant (WHO designation: Iota),[1] a SARS-CoV-2 VOI, was identified during Nov 2020 and quickly became a predominant variant in the New York City (NYC) area.[2-4] It has also been detected in all 52 states/territories in the US and at least 27 other countries (GISAID data,[5] as of 6/9/2021). An initial laboratory study[2] suggested that this variant is to some extent resistant to two therapeutic monoclonal antibodies in clinical use and neutralization by convalescent plasma and vaccinee sera. However, another study[4] examined all sequenced B.1.526 cases in NYC identified as of April 5, 2021 (n = 3,679) and showed preliminary evidence that this variant did not increase risk for infection after vaccination or reinfection. Both studies may be limited due to the small number of specimens available for analysis as well as delay in observation and reporting. Given these discrepancies, here we utilize detailed population epidemiological data collected since the beginning of the COVID-19 pandemic in NYC (March 1, 2020 – April 30, 2021) and multiple model-inference methods to estimate the transmissibility, immune escape potential, and disease severity of B.1.526.

METHODS
Study design and data

This study included three interconnected modeling analyses, synthesizing nine epidemiological and population datasets (Fig 1). The first analysis applied a network model-inference system to construct underlying SARS-CoV-2 transmission dynamics in NYC, accounting for under-detection of infection; it also enabled estimation of key population variables and parameters (e.g., the infection rate including those not detected as cases and transmission rate). The second analysis applied a city-level multi-variant, age-structured model to simulate and estimate the changes in transmissibility and immune escape potential for B.1.526 based on the network model-inference estimates and additional data (e.g., variant prevalence data). The last analysis utilized estimates from the first two model systems to estimate variant-specific infection fatality risk (IFR, i.e. the fraction of all persons with SARS-CoV-2 infection who died from the disease), for

112   B.1.526 and B.1.1.7, separately. Of note, here we refer to the combination of B.1.526-S:E484K
113   and B.1.526-S:S477N as B.1.526; we did not include B.1.526.1 (i.e., B.1.526-S:L452) based on
114   earlier lineage classification and available data showing lower prevalence of B.1.526.1.
115
For the network model-inference system, we utilized multiple sources of epidemiological data,
including confirmed and probable COVID-19 cases, emergency department (ED) visits, and
deaths, as well as vaccination data. As done previously,[6] we aggregated all COVID-19 confirmed
and probable cases[7,8] and deaths[8] reported to the NYC Department of Health and Mental
Hygiene (DOHMH) by age group (<1, 1-4, 5-14, 15-24, 25-44, 45-64, 65-74, and 75+ year-olds),
neighborhood of residence (42 United Hospital Fund neighborhoods in NYC[9]) and week of
occurrence (i.e., week of diagnosis for cases or week of death for decedents). COVID-19-related
ED visit data were obtained from the NYC syndromic surveillance system, comprised of all 53
hospital EDs in the city.[10] This system identified individuals presenting at the EDs with COVID-
like-illness (CLI; defined as having a fever and cough or sore throat or respiratory illness, or
pneumonia, or a COVID-19 discharge diagnosis code, excluding those with a discharge diagnosis
code of influenza only); in addition, CLI patients were matched to electronic laboratory reports
of SARS-CoV-2 tests with diagnosis date within ±7 days of ED visit. We estimated the number of
COVID-19-related ED visits as the number classified as CLI multiplied by the percentage of those
who tested positive for SARS-CoV-2 RNA, stratified by the same age and neighborhood groups
in weekly intervals. To account for the impact of vaccination, we also included COVID-19
vaccination data (partially and fully vaccinated, separately), aggregated to the same
age/neighborhood strata by week.
134
135   In addition, as in our previous study,[6] we used mobility data from SafeGraph[11] to model
136   changes in SARS-CoV-2 transmission rate due to non-pharmaceutical interventions. These data
137   were aggregated to the neighborhood level by week without age stratification.
138
For the multi-variant model analysis, we additionally utilized four city-level, weekly datasets: 1)
COVID-19 confirmed and probable cases, 2) hospitalizations,[12] 3) deaths, and 4) the percentage
of different variants in NYC based on genomic sequencing of samples submitted to the NYC
DOHMH Public Health Laboratory and Pandemic Response Laboratory.[4,13] The additional
hospitalization and variant percentage data were published by the NYC DOHMH[12,13] and
accessed on June 22, 2021. We used the variant data from the week starting Jan 31, 2021 to the
week starting April 25, 2021 in this analysis, because earlier weeks had very low sample sizes
(<200 samples sequenced per week).[13]
147

148 This study was classified as public health surveillance and exempt from ethical review and
149 informed consent by the Institutional Review Boards of both Columbia University and NYC
150 DOHMH.
151

Network model-inference system
The network model-inference system used here is similar to the approach described in Yang et
al;[6] however, here we further accounted for waning immunity and vaccination and additionally
used COVID-19-related ED visit data for model optimization. Briefly, the model-inference
system uses an epidemic model (Eqn 1) to simulate the transmission of SARS-CoV-2 by age
group and neighborhood, under implemented public health interventions and mass-vaccination
when vaccines became available starting Dec 14, 2020:
159

$$
\begin{cases}
\dfrac{dS_i}{dt} = \dfrac{R_i}{L} - \left(S_i \sum_{j=1}^{j=42} \dfrac{b_s b_j \beta_{city} m_{ij} I_j}{N_j}\right) - v_{i,1} - v_{i,2} \\[2mm]
\dfrac{dE_i}{dt} = \left(S_i \sum_{j=1}^{j=42} \dfrac{b_s b_j \beta_{city} m_{ij} I_j}{N_j}\right) - \dfrac{E_i}{Z} \\[2mm]
\dfrac{dI_i}{dt} = \dfrac{E_i}{Z} - \dfrac{I_i}{D} \\[2mm]
\dfrac{dR_i}{dt} = \dfrac{I_i}{D} + v_{i,1} + v_{i,2}
\end{cases}
\qquad [1]
$$

160
where S_i, E_i, I_i, R_i, and N_i are the number of susceptible, exposed (but not yet infectious),
infectious, and removed (either recovered or deceased) individuals and the total population,
respectively, from a given age group in neighborhood-i. β_{city} is the average citywide
transmission rate; b_s is the estimated seasonal trend.[6] The term b_i represents the
neighborhood-level transmission rate relative to the city average. The term m_{ij} represents the
changes in contact rate in each neighborhood (for $i=j$) or spatial transmission from
neighborhood-j to i (for $i \neq j$) and was computed based on the mobility data.[6] Z, $D,$ and L are the
latency period, infectious period, and immunity period, respectively. The term $v_{i,1}$ represents
the number of individuals in neighborhood-i successfully immunized after the first dose of the
vaccine and is computed using vaccination data and vaccine efficacy (VE) for 1st dose; $v_{i,2}$ is the
additional number of individuals successfully immunized after the second vaccine dose
(excluding those successfully immunized after the first dose). Because 97% of vaccine doses
administered in NYC during our study period (through April 30, 2021) were the Pfizer-BioNTech
or Moderna vaccines, we assumed a VE of 85% fourteen days after the first dose and 95% seven
days after the second dose based on clinical trials and real-word data.[14-16]
176

Using the model-simulated number of infections occurring each day, we further computed the
number of cases, ED visits, and deaths each week to match with the observations.[6] Similar to
the procedure for cases and deaths described in Yang et al.,[6] to compute the number of ED
visits, we multiplied the model-simulated number of new infections per day by the ED-
consultation rate (i.e. the fraction of model-simulated persons with new SARS-CoV-2 infections
presenting at the EDs), and further distribute these estimates in time per a distribution of time-
from-infection-to-ED-consultation (Table S1); we then aggregated the daily lagged, simulated
estimates to weekly totals for model inference.

Each week, the system uses the ensemble adjustment Kalman filter (EAKF)[17] to compute the
posterior estimates of model state variables and parameters based on the model (prior)
estimates and observed case, ED visit, and mortality data per Bayes' rule.[6] In particular, using
this model-inference, we estimated the citywide transmission rate (β_{city}), neighborhood
relative transmission rate (b_i), and IFR by age group for each week, from the week starting
March 1, 2020 (i.e. the beginning of the COVID-19 pandemic in NYC) to the week starting April
25, 2021.

Multi-variant, age-structured model
Due to model complexity, the model-inference system described above does not account for
the circulation of different variants. To model variants, we used a city-level multi-variant, age-
structured model,[18] per Eqn 2:

$$
\begin{cases}
\dfrac{dS_i^A}{dt} = \dfrac{R_i^A}{L_i^A} - \sum_j b_s mc_{ij} \sum_a \dfrac{\beta_j^{Aa} S_j^A I_j^a}{N^a} - \varepsilon_i - v_{i,1}^A - v_{i,2}^A \\[3mm]
\dfrac{dE_i^A}{dt} = \sum_j b_s mc_{ij} \sum_a \dfrac{\beta_j^{Aa} S_j^A I_j^a}{N^a} - \dfrac{E_i^A}{Z_i^A} + \varepsilon_i \\[3mm]
\dfrac{dI_i^A}{dt} = \dfrac{E_i^A}{Z_i^A} - \dfrac{I_i^A}{D_i^A} \\[3mm]
\dfrac{dR_i^A}{dt} = \dfrac{I_i^A}{D_i^A} - \dfrac{R_i^A}{L_i^A} + v_{i,1}^A + v_{i,2}^A
\end{cases}
\qquad [2]
$$

199
Model variables and parameters in Eqn 2 are similar to those in Eqn 1 with the same symbols.
For instance, β_i is the transmission rate for variant-*i*. However, instead of modeling the spatial
structure, Eqn 2 focuses on the interactions among different variants (indicated by the
subscript, *i*) and age structure (indicated by the superscript, *a* or *A*). Specifically, c_{ij} measures
the strength of cross-immunity to variant-*i* conferred by infection of variant-*j* (e.g., close to 0 if
it is weak and c_{ii}=1 for infection by the same variant). The vaccination model component $v_{i,1}^A$

and $v_{i,2}^A$ are also variant-specific and can additionally account for the reduction in VE against the

new variants if needed; however, here we used the same VE estimates for all variants included

(i.e., B.1.526, B.1.1.7, B.1.427 and B.1.429) based on observations.[4,16,19,20] Additionally, the term

ε_i represents travel-related importation of infections of variant-i (see Table S2).

We restricted this simulation to Nov 2020 – Apr 2021 (i.e., from the initial identification of

B.1.526 to before the further detection and increase of other variants such as Gamma and

Delta). In addition to preexisting variants of SARS-CoV-2 prior to Nov 2020 (hereafter referred

to as "non-VOC/VOI variants" for simplicity) and B.1.526, the model included B.1.1.7 and

B.1.427/B.1.429 (combined for simplicity), based on available genomic surveillance data

showing consistent detection of these variants during the simulation period and very low levels

for others if detected. Model parameters for B.1.1.7 and B.1.427/B.1.429 were listed in Table

S2. For simplicity, we did not account for other VOCs/VOIs variants because their percentages

were very low during either analysis period.[13]

Initial analysis based on the model-inference estimates suggested B.1.526 was around 20%

more infectious than non-VOC/VOI variants, without accounting for changes in immunity due to

potential immune escape (see details in Results). Therefore, in this analysis, we tested

combinations of change in transmissibility ranging from 10 – 30% increases and immune escape

ranging from 0 – 30%, both with a 5% increment and ±5% intervals (35 combinations in total).

For instance, for the combination centering at 10% transmissibility increase and 0% immune

escape, the model is initialized using values in the range of 5-15% (i.e., 10 ± 5%) transmissibility

increase and 0-5% (i.e., 0 ± 5% and setting negatives to 0) immune escape. In addition, due to

uncertainty on the initial prevalence, we tested three different levels of initial seeding for the

week starting Nov 1, 2020, i.e., low (0.5 – 2.5%), high (1.5 – 3.5%), and wider range (0.5 – 3.5%).

For reference, Washington Heights – Inwood (WHts), which is the neighborhood where the first

patients identified with B.1.526 resided and sought care, constituted 3.2% of the NYC

population in 2018. We initialized the model using the model-inference estimates (e.g.,

population susceptibility and transmission rates by age group; Table S2) and ran the model for

each parameter combination 10 times, each with 1000 realizations to account for model

stochasticity. Results are summarized from the 10,000 model realizations.

To identify the most plausible combination of transmissibility and immune escape properties

for B.1.526, we compared the model-estimated weekly number of cases, hospitalization, and

deaths as well as the percentage of the variants to available data. Evaluation was made based

on 1) accuracy, i.e., if the observation falls within the model-estimated interquartile range, it is

deemed accurate; 2) relative root-mean-square-error (RMSE) between the observed and the

model-estimated; and 3) Pearson correlation between the two time-series. Because results

show that model accuracy and relative RMSE had a wider spread among the combinations

tested (i.e., more distinctive), we first subset those having accuracy within the highest 25th

percentile and relative RMSE within the lowest 25th percentile (2-4 out of 35 combinations

remained for each setting of initial prevalence); we then selected the one with the highest

correlation in the subset as the best-performing and most plausible combination.

Estimating the changes in IFR due to B.1.526

The network model-inference system enables estimation of the IFR by age group over time.

These estimates are made combining all variants and do not distinguish by variant. However,

we reasoned that the combined IFR is a weighted average of individual, variant-specific

estimates given the relative prevalence of each variant. Accordingly, we built two linear

regression models to estimate the variant-specific IFR. Model 1 restricted the analysis to Nov

2020 – Jan 2021 (when the relative prevalence of B.1.1.7 in NYC was likely <10%; n = 14 weeks)

and only included two categories of variants:

$$IFR_{combined} \sim IFR_{B.1.526} i_{B.1.526} + IFR_{baseline} i_{others} \qquad [3]$$

259   Model 2 extended the analysis to Nov 2020 – Apr 2021 (n = 26 weeks) and included both

260   B.1.526 and B.1.1.7, in addition to other variants:

$$IFR_{combined} \sim IFR_{B.1.526} i_{B.1.526} + IFR_{B.1.1.7} i_{B.1.1.7} + IFR_{baseline} i_{others} \qquad [4]$$

In both models, *IFR_{combined}* is the overall IFR for each week, estimated using the model-inference

system; *i_{B.1.526}*, *i_{B.1.1.7}*, *i_{others}* are the percentage of infection by the corresponding variant for each

week, estimated using the multi-variant age-structured model with the most plausible

parameter combination as data are not available. *IFR_{baseline}* is the baseline IFR for the preexisting

variants, set to the average of model-inference estimates over the period of Oct – Nov 2020

(i.e., prior to the increase of the new variants). The variant-specific IFRs, *IFR_{B.1.526}* and *IFR_{B.1.1.7}*,

are then estimated using the regression models (n = 14 weekly data points for Model 1; and n =

26 weekly data points for Model 2). For either model, the change in IFR due to a given variant is

then computed as:

$$\Delta IFR = \frac{IFR_{variant} - IFR_{baseline}}{IFR_{baseline}} \times 100\% \qquad [5]$$

Both model analyses were performed for each age group or all ages combined, separately; we

also combined all those aged under 25 as the IFRs were similarly low for the four sub-age

groups (i.e. <1, 1-4, 5-14, and 15-24 year-olds).

RESULTS

Epidemic dynamics of the second pandemic wave in NYC

NYC experienced a very large first pandemic wave during spring 2020. Similar to our previous
work,[6] the model-inference system here estimates that 16.6% of the population (95% CrI: 13.6
– 21.5%; or 1.1 – 1.8 million people) had been infected by the end of May 2020 (i.e., end of the
first wave; Fig 2D). The city was able to gradually reopen part of its economy during summer
2020 after a 3-month long stay-at-home mandate for all non-essential workers. However,
infection resurged beginning in the fall of 2020 and the city experienced a second pandemic
wave around Nov 2020 – April 2021 (Fig 2). Following the second wave, an estimated total of
41.7% (95% CrI: 35.4 – 49.3%; or 3.0 – 4.1 million people) had been infected by the end of Apr
2021, including all those infected during the first wave. Note these estimates accounted for
under-detection of infections (Fig S1), for which the overall infection-detection rate increased
to 37.1% (95% CrI: 33.3 – 43.0%) during the 2nd wave from 15.1% (95% CrI: 11.7 – 18.5%) during
the 1st wave. This large number of infections occurred despite the non-pharmaceutical
interventions implemented throughout the pandemic and rollout of mass-vaccination starting
mid-Dec 2020. In addition, unlike the first wave that predominantly affected older age groups,
the second pandemic wave affected all age groups (Figs S2-3).
293
Transmission rate increased earliest in the neighborhood where B.1.526 was initially
identified
The emergence and rapid increase of B.1.526 coincided with the second pandemic wave in NYC.
While first reported in Feb 2021,[2] testing initially identified the B.1.526 variant in patient
samples dated back to early Nov 2020 from the city's WHts neighborhood.[2] As such, we first
examined potential changes in the transmission rate there. Indeed, prior to the identification of
B.1.526, estimated neighborhood relative transmission rate (b_i in Eqn 1) in WHts gradually
increased, remained at high levels during Nov 2020 – Feb 2021, and decreased to the baseline
level afterwards when B.1.526 became a predominant variant citywide (~40% of all cases
sequenced by end of Feb 2021). In comparison, the estimates were relatively stable for other
neighborhoods (Fig 3A), suggesting the changes in WHts were likely due to the early spread of
B.1.526. Averaging over this period, we estimate that the relative transmission rate in WHts
increased by 8.4% (95% CI: -5.8 – 22.5%). Concurrently, the citywide transmission rate
increased by 13.3% (95% CI: -21.1 – 47.8%; Fig 3B). These two preliminary estimates in
combination suggest that the transmission rate of B.1.526 likely is 22.8% (95% CI: -12.4 –
58.0%) higher than preexisting non-VOC/VOI variants, without accounting for potential change
due to immune evasion.
311
B.1.526 likely causes a moderate increase in transmissibility (15-25%) and slight immune
evasion (0-10%)
We further examine model estimations under a wide range of transmissibility and immune
escape settings for B.1.526. Under all three possible scenarios of initial prevalence (i.e., 0.5 –

2.5%, 1.5 – 3.5%, and 0.5 – 3.5%), model simulations consistently show that B.1.526 likely
increases transmissibility by 15-30% and can escape immunity in 0-10% of previously infected
persons (Fig 4 A-C). Overall, a higher initial prevalence (1.5 – 3.5% at the beginning of Nov 2020)
combining with a 15-25% increase in transmissibility and 0-10% immune escape (Fig 4 A-C,
middle column; and Fig 4D) generated the most accurate estimates of cases, hospitalizations
and deaths as well as variant percentages during the second wave. Model simulations show
that, with this moderate increase in transmissibility and small immune escape, B.1.526 was able
to outcompete preexisting variants and gradually increase its percentage from Nov 2020 to
March 2021; however, afterwards its percentage decreased with the surge of B.1.1.7, a more
infectious variant (Fig 4D, bottom right panel).
326
B.1.526 likely increases disease severity substantially
During the second wave, estimated IFR increased gradually in later months, particularly among
older age groups, despite the decline in deaths following mass-vaccination (Fig 5). Modeling
accounting for infections and deaths due to B.1.526, B.1.1.7, and non-VOC/VOI variants
suggests that B.1.526 increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64
year-olds [absolute IFR: 0.42% (95% CI: 0.31 – 0.54%) vs. 0.29% (95% CI: 0.15 – 0.44%) baseline
risk]; 82% (95% CI: 20 – 140%) among 65-74 year-olds [absolute IFR: 1.9% (95% CI: 1.2 – 2.5%)
vs. 1.0% (95% CI: 0.57 – 2.5%) baseline risk], and 62% (95% CI: 45 – 80%) among 75+ [absolute
IFR: 6.7% (95% CI: 5.9 – 7.4%) vs. 4.1% (95% CI: 2.2 – 6.3%) baseline risk], during Nov 2020 – Apr
2021; overall, B.1.526 increased the IFR by 60% (95% CI: 38 – 82%), compared to estimated
baseline risk (Table 1). The analysis restricting to Nov 2020 – Jan 2021 suggests similar IFR
increases (Table S3). These estimated IFR increases were lower than for B.1.1.7 but
comparable. Of note, the IFRs for B.1.1.7 estimated here were higher than but in line with those
reported in the UK [e.g., overall increase: 100% (75-130%) vs. 61% (42–82%) in the UK[21]].
341
DISCUSSION
The B.1.526 variant is one of the SARS-CoV-2 variants designated as a VOI by both the WHO[1]
and the US CDC.[18] However, due to a lack of extensive genomic sequencing and contact tracing
data particularly during the early phase of its emergence, its key epidemiological properties
have not been well characterized. Utilizing multiple epidemiological datasets and
comprehensive modeling, here we have estimated the changes in transmissibility, immune
escape potential, and disease severity for B.1.526. Results suggest that, compared to
preexisting non-VOC/VOI variants, B.1.526 causes a moderate increase in transmissibility and
minimal immune evasion; however, it might substantially increase IFR in older adults. As such,
continued monitoring of the circulation of this variant is warranted.
352

Our study offers several lessons for future outbreak response. First, prior to the emergence of
B.1.526, the estimated transmission rate in WHts, where it likely emerged, was consistently
higher than other neighborhoods in NYC throughout the pandemic. Population characteristics
(e.g., household structure) that may contribute to this higher transmission rate need further
investigation; however, the higher transmission rate may have facilitated the spread of new
mutants between hosts and its emergence population-wide. It is thus important to closely
monitor populations with sustained higher transmission rates for new variants, particularly in
areas lacking robust and timely sequencing of samples from newly identified cases. In addition,
the estimated transmission rate in WHts further increased in conjunction with the emergence
of B.1.526; such changes thus may serve as an early indicator for in-depth epidemiological
investigation (e.g., to assess changes in circulating variants and transmissibility). A similar
approach has been applied in the UK, where subregions with higher estimated growth rates
were prospectively investigated, leading to identification of B.1.1.7 as a VOC.[22-25]
366
Second, we did not find a higher B.1.526-related IFR among younger age groups (those under
45 years); this finding is consistent with the findings of Thompson et al.[4] based on analysis of all
sequenced cases, the majority of whom (67%) were under 45 years. However, for older ages,
we found substantially higher B.1.526-related IFRs (e.g. >60% higher for those above 65 years).
This latter finding appears to be consistent with the report by Annavajhala et al.[2] showing
resistance of B.1.526 to therapeutic antibodies. Over the course of the pandemic, SARS-CoV-2
IFR has decreased substantially (about a 3-fold difference between the two pandemic waves),
likely due to improved medical treatments (e.g., therapeutic antibodies), better patient
management, and earlier diagnosis. As older adults are more likely to suffer from severe
COVID-19 and thus receive therapeutic antibodies,[26,27] the resistence of B.1.526 may render
these treatments ineffective despite their prior success against other variants, leading to
increases in IFR among older adults. These findings highlight the importance of monitoring the
efficacy of therapeutics against different variants and timely update of treatments. In addition,
a better understanding of factors contributing to the higher IFRs in certain variants is warranted
to inform countermeasures.[28,29]
382
Lastly, our analyses suggest both B.1.526 and B.1.1.7 likely had been spreading in the
population for weeks or months prior to detection by the surveillance system.[2,3,30] Expanding
genomic sequencing programs for SARS-CoV-2 and improving linkage to epidemiologic data can
improve detection of new VOIs/VOCs. Such efforts are underway (e.g., in the US) but more
efforts and resources are urgently needed globally. In addition, to support more timely
detection and control, targeted screening of key subpopulations (e.g., those prospectively
identified from modeling as having high transmission rates) and viral traits (e.g., mutations
linked to increased transmissibility and/or immune evasion as done in Annavajhala et al.[2]) is

needed, as well as timely sharing of key information globally. The documentation of new
VOIs/VOCs anywhere in the world then should prompt preparedness measures to detect and
rapidly respond to the introduction of those variants into local areas. More fundamentally, to
limit emergence of new VOIs/VOCs and end the COVID-19 pandemic, all populations worldwide
should have timely access to vaccination, and multiple layers of mitigation efforts are needed
until a sufficient portion of the population is protected by vaccination.
397
Our study also has several limitations. First, most of our analyses are based on population-level
data without variant-specific information, given limited variant testing during most of the study
period. We circumvented this data deficiency by analyzing estimates of a key subpopulation
(e.g., the WHts neighborhood where B.1.526 was initially detected) and leveraging prior
knowledge (e.g., estimated IFR prior to B.1.526 emergence). Second, our study did not
distinguish the two subclades within the B.1.526 lineage – one containing the E484K mutation
and the other containing the S477N mutation. Both the E484K and S477N mutations have been
shown to mediate immune escape;[29,31-33] in addition, the percentages of these two subclades
were similar during our study period, suggesting they likely have similar epidemiological
characteristics. Lastly, there is a likely larger uncertainty in B.1.526-related and B.1.1.7-related
IFR estimates for younger ages (those under 45), due to the smaller number of deaths and
larger uncertainty in baseline IFR estimates. Future investigation addressing these issues is
warranted should a large sample of variant-specific data become available.
411
412   In summary, our study has reconstructed the early epidemic trajectory and subsequent rise of
413   B.1.526 in NYC and estimated its key epidemiological properties. Findings highlight the
414   importance of monitoring the viral diversity of SARS-CoV-2, epidemiological characteristics of
415   new variants, and disease severity, as COVID-19 remains a global public health threat.
416

Acknowledgments:
This study was supported by the National Institute of Allergy and Infectious Diseases (AI145883)
and the NYC DOHMH. We thank Columbia University Mailman School of Public Health for high
performance computing, Safe Graph (safegraph.com) for providing the mobility data, and
Sasikiran Kandula at Columbia University for compiling the mobility data used in this study. We
thank the NYC DOHMH Incident Command System Surveillance and Epidemiology Section for
processing, cleaning, and managing COVID-19 surveillance data, the NYC DOHMH Public Health
Laboratory and Pandemic Response Laboratory for generating and analyzing sequence data,
and Iris Cheng, Mohammed Almashhadani, Charles Ko, and Jaimie Shaff from the NYC DOHMH
for providing the vaccination data and helpful suggestions on the manuscript.

Author contributions:

WY designed the study, conducted the analysis, and wrote the first draft; SKG contributed to
study coordination and specification of COVID-19 case data, and provided input on parameter
estimation; ERP led aggregation and provision of COVID-19 case data; LG contributed to
management of COVID-19 case data; WL provided the COVID-19-associated mortality data; RM
and RL oversaw the collection of and provided the COVID-19 ED data; SH and JW provided input
on SARS-CoV-2 variants and interpretation of the NYC variant percentage data; AF oversaw data
collection and management processes at DOHMH. All authors contributed to the final draft.
436

Conflict of Interest
438 The authors declare no conflict of interest.
439

References

1. World Health Organization. Tracking SARS-CoV-2 variants. 2021.
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
2. Annavajhala MK, Mohri H, Wang P, et al. A Novel and Expanding SARS-CoV-2 Variant,
B.1.526, Identified in New York. *medRxiv* 2021: 2021.02.23.21252259.
3. West AP, Wertheim JO, Wang JC, et al. Detection and characterization of the SARS-CoV-2
lineage B.1.526 in New York. *bioRxiv* 2021: 2021.02.14.431043.
4. Thompson CN, Hughes S, Ngai S, et al. Rapid Emergence and Epidemiologic Characteristics
of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021.
MMWR Morbidity and mortality weekly report 2021; **70**(19): 712-6.
5. Global Initiative on Sharing All Influenza Data (GISAID). GISAID. 2021.
https://www.gisaid.org (accessed 6/9/2021 2021).
6. Yang W, Kandula S, Huynh M, et al. Estimating the infection-fatality risk of SARS-CoV-2 in
New York City during the spring 2020 pandemic wave: a model-based analysis. *The Lancet*
Infectious diseases 2021; **21**(2): 203-12.
7. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance
System (NNDSS) - Coronavirus Disease 2019 (COVID-19). 4/16/2021 2021.
https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/ (accessed
6/22/21 2021).
8. New York City Department of Health and Mental Hygiene. Defining confirmed and probable
cases and deaths. 2020. https://www1.nyc.gov/site/doh/covid/covid-19-data.page
(accessed 5/27/2021 2021).
9. NewYork City Department of Health and Mental Hygiene. NYC UHF 42 Neighborhoods.
http://a816-dohbesp.nyc.gov/IndicatorPublic/EPHTPDF/uhf42.pdf.
10. Lall R, Abdelnabi J, Ngai S, et al. Advancing the Use of Emergency Department Syndromic
Surveillance Data, New York City, 2012-2016. *Public Health Rep* 2017; **132**: 23s-30s.

11. SafeGraph. Weekly Patterns: Foot Traffic Data To Understand The COVID-19 Pandemic.
2020. https://www.safegraph.com/weekly-foot-traffic-patterns.
12. New York City Department of Health and Mental Hygiene. NYC Coronavirus Disease 2019
(COVID-19) Data. https://github.com/nychealth/coronavirus-data.
13. New york City Department of Health and Mental Hygiene. Variants. 2021.
https://github.com/nychealth/coronavirus-data/tree/master/variants (accessed 6/22/21
2021).
14. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
Vaccine. *New Engl J Med* 2020.
15. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
Vaccine. *N Engl J Med* 2021; **384**(5): 403-16.
16. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2
vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths
following a nationwide vaccination campaign in Israel: an observational study using national
surveillance data. *The Lancet* 2021; **397**(10287): 1819-29.
17. Anderson JL. An Ensemble Adjustment Kalman Filter for Data Assimilation. *Mon Weather*
Rev 2001; **129**(12): 2884-903.
18. Yang W, Shaman J. Epidemiological characteristics of three SARS-CoV-2 variants of concern
and implications for future COVID-19 pandemic outcomes. *medRxiv* 2021:
2021.05.19.21257476.
19. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine
against the B.1.1.7 and B.1.351 Variants. *New Engl J Med* 2021.
20. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape
neutralization by vaccine-induced humoral immunity. *Cell* 2021; **184**(9): 2372-83 e9.
21. Davies NG, Jarvis CI, Group CC-W, et al. Increased mortality in community-tested cases of
SARS-CoV-2 lineage B.1.1.7. *Nature* 2021; **593**(7858): 270-4.
22. New and Emerging Respiratory Virus Threats Advisory Group. Minutes of the NERVTAG
COVID-19 FortiethMeeting: 11 December 2020. 2020.
https://app.box.com/s/3lkcbxepqixkg4mv640dpvvg978ixjtf/file/789097594594 (accessed
7/27/21 2021).
23. New and Emerging Respiratory Virus Threats Advisory Group. Minutes of the extraordinary
meeting of NERVTAG COVID-19 and SPI-M on SARS-CoV-2 variants: 21 December 2020.
2020. https://app.box.com/s/3lkcbxepqixkg4mv640dpvvg978ixjtf/file/789098622117
(accessed 7/27/21 2021).
24. New and Emerging Respiratory Virus Threats Advisory Group. NERVTAG/SPI-M
Extraordinary meetingon SARS-CoV-2 variant of concern 202012/01 (variant B.1.1.7). 2020.
https://app.box.com/s/3lkcbxepqixkg4mv640dpvvg978ixjtf/file/756964987830 (accessed
7/27/21 2021).

25. Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England:
Insights from linking epidemiological and genetic data. *medRxiv* 2021:
2020.12.30.20249034.
26. National Institutes of Health. COVID-19 Treatment Guildlines: Anti-SARS-CoV-2 Monoclonal
Antibodies. 5/24/2021. https://www.covid19treatmentguidelines.nih.gov/therapies/anti-
sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/ (accessed 7/6/2021.
27. Centers for Disease Control and Prevention. COVID-19: Treatment considerations for
healthcare providers. 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-
info.html.
28. Starr TN, Greaney AJ, Addetia A, et al. Prospective mapping of viral mutations that escape
antibodies used to treat COVID-19. *Science* 2021; **371**(6531): 850-+.
29. Greaney AJ, Starr TN, Gilchuk P, et al. Complete Mapping of Mutations to the SARS-CoV-2
Spike Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host & Microbe*
2021; **29**(1): 44-57.e9.
30. Washington NL, Gangavarapu K, Zeller M, et al. Emergence and rapid transmission of SARS-
CoV-2 B.1.1.7 in the United States. *Cell* 2021; **184**(10): 2587-+.
31. Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the
SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma
antibodies. *Cell Host & Microbe* 2021; **29**(3): 463-76.e6.
32. Liu Z, VanBlargan LA, Bloyet L-M, et al. Identification of SARS-CoV-2 spike mutations that
attenuate monoclonal and serum antibody neutralization. *Cell host & microbe* 2021; **29**(3):
477-88.e4.
33. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and
immune escape. *Nature Reviews Microbiology* 2021; **19**(7): 409-24.
528

Table and Figure Captions

Table 1. Estimated IFR for different variants and changes compared to the baseline risk estimated for preexisting variants during Oct – Dec 2020, using Eqn 4.

Fig 1. Study design. This study included three modeling analyses: 1) spatial network model-inference to construct the transmission dynamics and estimate key population variables and parameters by United Hospital Fund (UHF) neighborhood of residence and age group; 2) city-level multi-variant, age-structured modeling to simulate and estimate the changes in transmissibility and immune escape potential for B.1.526; and 3) linear regression models to estimate variant-specific infection fatality risk (IFR), for B.1.526 and B.1.1.7, separately. Nine datasets (listed in the black open boxes) were used as model inputs or to evaluate the accuracy of model estimates (indicated for each dataset below). Models used are shown in the blue filled boxes and model outputs are listed in the blue open boxes (key estimates reported in detail in the Results are bolded). Connections among the analyses are indicated by the arrows and associated annotations.

Fig 2. Model fit and key estimates. Upper panel shows model-fit to weekly number of cases (A), ED visits (B), and deaths (C), for all ages combined. Lower panel shows key model-inference estimates of weekly number of infections including those not detected as cases (D), cumulative number of infections in NYC overall (E), and cumulative infection rate by neighborhood (F). Boxes show model estimates (thick horizontal lines and box edges show the median, 25th, and 75th percentiles; vertical lines extending from each box show 95% CrI) and red dots show corresponding. For the weekly estimates, week starts (mm/dd/yy) are shown in the x-axis labels. Star (*) in the map indicates the location of the Washington Heights – Inwood neighborhood.

Fig 3. Changes in transmission rate. (A) Changes in neighborhood-level relative transmission rate. (B) Changes in citywide transmission rate. Vertical dashed lines indicate the earliest date B.1.526 was identified as reported in Annavajhala et al. Labels of x-axis show the week starts (mm/dd/yy).

Fig 4. Comparison of different combinations of changes in transmissibility and immune escape property for B.1.526. Left panel shows the overall accuracy (A), relative RMSE (B), and correlation (C) of model estimates under different transmissibility and immune escape settings. White crosses (x) indicate the best-performing parameter combination. Right panel shows model estimates using the overall best-performing parameter combination (i.e., 1.5-3.5% initial prevalence, 15-25% higher transmissibility, and 0-10% immune escape). Lines and surrounding areas show model-simulated median estimates and interquartile range; dots show

corresponding observations; colors indicate different variants as specified in the legend. Note
that these model simulations used same infection-detection rate, hospitalization-rate and IFR
(i.e., average during Nov 2020 – Apr 2021); that is, they did not account for changes in case
ascertainment or disease severity by week during this period, due to, e.g., increases in disease
severity by the new variants. As such, there were larger deviations from the observations
during later months of the simulation with more infections by the new variants.
573
574   **Fig 5.** Estimated infection fatality risk. Red lines show the estimated median IFR with
575   surrounding areas indicating the 50% (darker color) and 95% (lighter color) CrI. For comparison,
576   the grey bars show the number of deaths reported for each week from the week of Oct 4, 2020
577   to Apr 25, 2021. X-axis labels show the week starts (mm/dd/yy).
578
579
Supplemental Table and Figure Captions
Table S1. Prior ranges for the network model-inference system. The prior ranges are similar to
Table S1 of Yang et al.[1] but include additional parameters in Eqn 1. The spatial, temporal, and
age resolution of each parameter or variable, estimated in the model-inference system, is
specified in the column "Resolution". Note posterior parameter estimates can extend outside
the specified prior ranges.
586
Table S2. Initial conditions used to simulate co-circulation of different variants in the multi-
variant, age-structured model. To partially account for changing infection-detection rate, ED-
consultation rate (EDR) and IFR, for these three parameters, we used the model-inference
estimates averaged over the entire simulation period (i.e. Nov 2020 – April 2021). For the initial
transmission rate (for the preexisting non-VOC/VOI variants), we used the model-inference
estimates averaged over the week of 10/25/2020 – the week of 11/7/2020 (i.e. the 3 weeks
around the start of simulation). For the rest of model state variables and parameters, we used
model-inference estimates made at the week of 10/25/2020. For B.1.1.7, we used the
following ranges based on estimates from Yang and Shaman[10]: 40.3 – 52.3% higher
transmissibility (related to estimates for the preexisting non-VOC/VOI variants listed below) and
0 – 10% immune escape; for comparison, contact tracing data from the UK showed that B.1.1.7
was 30-50% more infectious.[11] For B.1.427/ B.1.429, we used the following ranges based on
estimates from Deng et al.[12]: 16 – 24% higher transmissibility and 0-10% immune escape (vs.
21.4 – 27.8% increase in transmission rate in Deng et al.[12] without accounting for changes in
immunity due to potential immune escape).
602
Table S3. Estimated IFR for different variants and changes compared to the baseline risk
estimated for preexisting variants during Oct – Dec 2020, using Eqn 3.

Fig S1. Estimated infection-detection rate by age group. Red lines show the estimated median

infection-detection rate with surrounding areas indicating the 50% (darker color) and 95%

(lighter color) CrI. For comparison, the grey bars show the number of cases reported for each

week from the week of Oct 4, 2020 to Apr 25, 2021. Labels of x-axis show the week starts

(mm/dd/yy).

Fig S2. Model-fit by age group. Boxes show model estimates (thick horizontal lines and box

edges show the median, 25th, and 75th percentiles; vertical lines extending from each box show

95% CrI) and red dots show corresponding.

Fig S3. Estimated cumulative infection rates by age group. Thick horizontal lines and box edges

show the median, 25th, and 75th percentiles; vertical lines extending from each box show 95%

CrI.

Table and Figures

620 **Table 1.** Estimated IFR for different variants and changes compared to the baseline risk estimated for preexisting variants during Oct
621 – Dec 2020, using Eqn 4.

Age	IFR, baseline (%)	IFR, B.1.526 (%)	IFR, B.1.1.7 (%)	Changes, B.1.526 (%)	Changes, B.1.1.7 (%)	Model goodness-of-fit (R^2)
<25	0.004 (0.0021, 0.0059)	0.004 (0.0039, 0.0041)	0.004 (0.0039, 0.0042)	-0.61 (-3.5, 2.3)	0.97 (-2.8, 4.8)	1
25-44	0.04 (0.021, 0.059)	0.037 (0.034, 0.04)	0.043 (0.039, 0.047)	-6 (-13, 1.4)	8.4 (-1.9, 19)	1
45-64	0.29 (0.15, 0.44)	0.42 (0.31, 0.54)	0.51 (0.35, 0.67)	46 (7.4, 84)	76 (22, 130)	0.97
65-74	1 (0.57, 2.5)	1.9 (1.2, 2.5)	3.3 (2.4, 4.2)	82 (20, 140)	210 (130, 300)	0.96
75+	4.1 (2.2, 6.3)	6.7 (5.9, 7.4)	8 (7, 9)	62 (45, 80)	95 (71, 120)	0.99
all	0.35 (0.2, 0.58)	0.56 (0.48, 0.63)	0.72 (0.61, 0.82)	60 (38, 82)	100 (75, 130)	0.99

Fig 1. Study design. This study included three modeling analyses: 1) spatial network model-
inference to construct the transmission dynamics and estimate key population variables and
parameters by United Hospital Fund (UHF) neighborhood of residence and age group; 2) city-
level multi-variant, age-structured modeling to simulate and estimate the changes in
transmissibility and immune escape potential for B.1.526; and 3) linear regression models to
estimate variant-specific infection fatality risk (IFR), for B.1.526 and B.1.1.7, separately. Nine
datasets (listed in the black open boxes) were used as model inputs or to evaluate the accuracy
of model estimates (indicated for each dataset below). Models used are shown in the blue filled
boxes and model outputs are listed in the blue open boxes (key estimates reported in detail in
the Results are bolded). Connections among the analyses are indicated by the arrows and
associated annotations.

Fig 2. Model fit and key estimates. Upper panel shows model-fit to weekly number of cases (A), ED visits (B), and deaths (C), for all ages combined. Lower panel shows key model-inference estimates of weekly number of infections including those not detected as cases (D), cumulative number of infections in NYC overall (E), and cumulative infection rate by neighborhood (F). Boxes show model estimates (thick horizontal lines and box edges show the median, 25th, and 75th percentiles; vertical lines extending from each box show 95% CrI) and red dots show corresponding. For the weekly estimates, week starts (mm/dd/yy) are shown in the x-axis labels. Star (*) in the map indicates the location of the Washington Heights – Inwood neighborhood.

646 **Fig 3.** Changes in transmission rate. (A) Changes in neighborhood-level relative transmission
647 rate. (B) Changes in citywide transmission rate. Vertical dashed lines indicate the earliest date
648 B.1.526 was identified as reported in Annavajhala et al. Labels of x-axis show the week starts
649 (mm/dd/yy).

650
651

Fig 4. Comparison of different combinations of changes in transmissibility and immune escape property for B.1.526. Left panel shows the overall accuracy (A), relative RMSE (B), and correlation (C) of model estimates under different transmissibility and immune escape settings. White crosses (x) indicate the best-performing parameter combination. Right panel shows model estimates using the overall best-performing parameter combination (i.e., 1.5-3.5% initial prevalence, 15-25% higher transmissibility, and 0-10% immune escape). Lines and surrounding areas show model-simulated median estimates and interquartile range; dots show corresponding observations; colors indicate different variants as specified in the legend. Note that these model simulations used same infection-detection rate, hospitalization-rate and IFR (i.e., average during Nov 2020 – Apr 2021); that is, they did not account for changes in case ascertainment or disease severity by week during this period, due to, e.g., increases in disease severity by the new variants. As such, there were larger deviations from the observations during later months of the simulation with more infections by the new variants.

Fig 5. Estimated infection fatality risk. Red lines show the estimated median IFR with surrounding areas indicating the 50% (darker color) and 95% (lighter color) CrI. For comparison, the grey bars show the number of deaths reported for each week from the week of Oct 4, 2020 to Apr 25, 2021. X-axis labels show the week starts (mm/dd/yy).

 Supplemental Tables and Figures

 Table S1. Prior ranges for the network model-inference system. The prior ranges are similar to

 Table S1 of Yang et al.[1] but include additional parameters in Eqn 1. The spatial, temporal, and

 age resolution of each parameter or variable, estimated in the model-inference system, is

 specified in the column "Resolution". Note posterior parameter estimates can extend outside

 the specified prior ranges.

Parameter/ variable	Symbol	Resolution	Prior range	Source/rationale
Initial exposed	$E(t=0)$	neighborhood- and age-group specific, estimated for the beginning of the Week of March 1, 2020	300 – 8000 total citywide, scaled by population size for each age group and neighborhood	Large uncertainties, used very wide range
Initial infectious	$I(t=0)$	neighborhood- and age-group specific, estimated for the beginning of the Week of March 1, 2020	150 – 4000 total citywide, scaled by population size for each age group and neighborhood	Assumed to be half the initial exposed
Initial susceptible	$S(t=0)$	neighborhood- and age-group specific, estimated for the beginning of the Week of March 1, 2020	$N - E - I$	Assumed all were susceptible except for those initially exposed/infectious
Population size in each age group and neighborhood	N	neighborhood- and age-group specific	N/A	NYC intercensal population estimates for 2018[2]
Citywide transmission rate	β_{city}	Citywide, age-group specific, estimated for each week	[0.5, 1] per day overall; scaled by contact rate for each age group based on contact data from the POLYMOD study[3] (averaged across 8 countries)	Based on R_0 estimates of around 1.5-4 for SARS-CoV-2[4-6]

Scaling of neighborhood transmission rate	b_i	neighborhood- and age-group specific, estimated for each week	[0.8, 1.2] for age groups under 65 years; [0.5, 1.5] for age groups 65 or older	Around 1; larger variation for elderly groups based on data
Latency period	Z	Citywide, age-group specific, estimated for each week	[2, 5] days	Incubation period: 5.2 days (95% CI: 4.1, 7)[4]; latency period is likely shorter than the incubation period
Infectious period	D	Citywide, age-group specific, estimated for each week	[2, 5] days	Time from symptom onset to hospitalization: 3.8 days (95% CI: 0, 12.0) in China,[7] plus 1-2 days viral shedding before symptom onset. We did not distinguish symptomatic/asymptomatic infections.
Immunity period	L	Citywide, age-group specific, estimated for each week	[2.5, 3.5] years	Based on estimated immunity period for endemic human coronaviruses (see Appendix of Yang et al.[1])
Multiplicative factor for mobility; see Yang et al.[1] for detail	m_1	Citywide, age-group specific, estimated for each week	[1, 2] for <1 year; [0.5, 1.5] for three age groups 1-24 years; [0.1, 1.5] for age group 25-44; [1, 2.5] for age groups 45 or older	Initial model testing showed transmission rates for younger age groups were more sensitive to changes in mobility whereas the two oldest age groups were not sensitive to mobility. For age groups with contact rates lower than the average (based

				on the POLYMOD study[3]), we raised the diagonal elements in the mobility matrix to the power of the relative contact rate (<1) to account for insensitivity of transmission rate in these age groups to mobility.
Multiplicative factor for neighborhood connectivity; see Yang et al.[1] for detail	m_2	Citywide, age-group specific, estimated for each week	[0.5, 2]	Likely around 1 but with large uncertainties
Mean of time from viral shedding to diagnosis; see Yang et al.[1] for detail	T_m	Citywide, age-group specific, estimated for each week	[3, 8] days	From a few days to a week from symptom onset to diagnosis,[7] plus 1-2 days of viral shedding (being infectious) before symptom onset
Standard deviation (SD) of time from viral shedding to diagnosis; see Yang et al.[1] for detail	T_{sd}	Citywide, age-group specific, estimated for each week	[1, 3] days	To allow variation in time to diagnosis
Infection-detection rate; see Yang et al.[1] for detail	r	Citywide, age-group specific, estimated for each week	Starting from [0.001, 0.05] at time 0 and allowed to increase over time using space re-probing[8]	Large uncertainties

Infection fatality risk (IFR); see Yang et al.[1] for detail	Citywide, age-group specific, estimated for each week	$[5, 15]\times10^{-5}$ for ages under 25; $[5, 15]\times10^{-4}$ for ages 25-44; $[5, 15]\times10^{-3}$ for ages 45-64; $[0.01, 0.1]$ for ages 65-74; $[0.02, 0.2]$ for ages 75+;	Based on previous estimates[9] but extend to have wider ranges
Time from diagnosis to death; see Yang et al.[1] for detail	Citywide	Gamma distribution with mean of 9.36 days and SD of 9.76 days	Based on n=15,686 COVID-19 confirmed deaths in NYC as of May 17, 2020.
ED consultation rate (EDR)	Citywide, age-group specific, estimated for each week	$[0.001, 0.02]$ for ages under 25; $[0.003, 0.03]$ for ages 25-44; $[0.006, 0.06]$ for ages 45-64; $[0.01, 0.15]$ for ages 65-74; $[0.02, 0.25]$ for ages 75+;	Based on the ratio of total ED visits and estimated infections during March – Dec 2020
Time-from-infectiousness -to-ED or hospitalization	Citywide, for all ages	Gamma distribution with mean of $[5, 7]$ days and SD of $[2, 4]$ days	

678
679

Table S2. Initial conditions used to simulate co-circulation of different variants in the multi-variant, age-structured model. To partially account for changing infection-detection rate, ED-consultation rate (EDR) and IFR, for these three parameters, we used the model-inference estimates averaged over the entire simulation period (i.e. Nov 2020 – April 2021). For the initial transmission rate (for the preexisting non-VOC/VOI variants), we used the model-inference estimates averaged over the week of 10/25/2020 – the week of 11/7/2020 (i.e. the 3 weeks around the start of simulation). For the rest of model state variables and parameters, we used model-inference estimates made at the week of 10/25/2020. For B.1.1.7, we used the following ranges based on estimates from Yang and Shaman[10]: 40.3 – 52.3% higher transmissibility (related to estimates for the preexisting non-VOC/VOI variants listed below) and 0 – 10% immune escape; for comparison, contact tracing data from the UK showed that B.1.1.7 was 30-50% more infectious.[11] For B.1.427/ B.1.429, we used the following ranges based on estimates from Deng et al.[12]: 16 – 24% higher transmissibility and 0-10% immune escape (vs. 21.4 – 27.8% increase in transmission rate in Deng et al.[12] without accounting for changes in immunity due to potential immune escape).

variant	parameter	lower bound	upper bound
B.1.526	Low initial prevalence (%)	0.5	2.5
B.1.526	High initial prevalence (%)	1.5	3.5
B.1.526	Wide initial prevalence (%)	0.5	3.5
B.1.1.7	Increase in transmission rate	0.403	0.5227
B.1.1.7	Immune escape	0	0.1
B.1.427/9	Increase in transmission rate	0.16	0.24
B.1.427/9	Immune escape	0	0.1
non-VOC/VOI	Travel-related importation ε_i	Nominally set to 1 per week for the entire city (N = 8.4 million people)	
B.1.526	Travel-related importation ε_i	Set to 0 as it emerged locally	
B.1.1.7	Travel-related importation ε_i	For the entire city (N = 8.4 million), set to 1 per 2 days for 11/1 – 11/15/20 to reflect lower initial seeding, 1.5 per day for 11/16 -12/31/20 to reflect higher seeding during the holidays, and 2 per day for 1/1 – 4/30/21 to reflect higher seeding due to increases in these variants in the US. Same settings were used for B.1.1.7 and B.1.427/9, because once local transmission is established, travel-related importation plays a nominal role.	
B.1.427/9	Travel-related importation ε_i		

non-VOC/VOI	β_{11} (per day, same below)	0.14	0.21
non-VOC/VOI	β_{22}	0.15	0.2
non-VOC/VOI	β_{33}	0.16	0.22
non-VOC/VOI	β_{44}	0.16	0.23
non-VOC/VOI	β_{55}	0.24	0.36
non-VOC/VOI	β_{66}	0.17	0.25
non-VOC/VOI	β_{77}	0.17	0.22
non-VOC/VOI	β_{88}	0.19	0.25
non-VOC/VOI	β_{12}	0.071	0.1
non-VOC/VOI	β_{13}	0.018	0.027
non-VOC/VOI	β_{14}	0.0074	0.011
non-VOC/VOI	β_{15}	0.023	0.034
non-VOC/VOI	β_{16}	0.011	0.015
non-VOC/VOI	β_{17}	0.0075	0.011
non-VOC/VOI	β_{18}	0.0052	0.0075
non-VOC/VOI	β_{21}	0.074	0.1
non-VOC/VOI	β_{23}	0.019	0.026
non-VOC/VOI	β_{24}	0.0078	0.011
non-VOC/VOI	β_{25}	0.024	0.033
non-VOC/VOI	β_{26}	0.011	0.015
non-VOC/VOI	β_{27}	0.0079	0.011
non-VOC/VOI	β_{28}	0.0054	0.0074
non-VOC/VOI	β_{31}	0.02	0.028
non-VOC/VOI	β_{32}	0.02	0.028
non-VOC/VOI	β_{34}	0.0098	0.014
non-VOC/VOI	β_{35}	0.013	0.018
non-VOC/VOI	β_{36}	0.0072	0.01
non-VOC/VOI	β_{37}	0.0051	0.0071
non-VOC/VOI	β_{38}	0.0066	0.0091
non-VOC/VOI	β_{41}	0.0085	0.013
non-VOC/VOI	β_{42}	0.0085	0.013
non-VOC/VOI	β_{43}	0.013	0.02
non-VOC/VOI	β_{45}	0.014	0.021
non-VOC/VOI	β_{46}	0.01	0.015
non-VOC/VOI	β_{47}	0.0037	0.0054
non-VOC/VOI	β_{48}	0.0069	0.01
non-VOC/VOI	β_{51}	0.11	0.17
non-VOC/VOI	β_{52}	0.11	0.17

non-VOC/VOI	β_{53}	0.092	0.14
non-VOC/VOI	β_{54}	0.073	0.11
non-VOC/VOI	β_{56}	0.07	0.11
non-VOC/VOI	β_{57}	0.042	0.064
non-VOC/VOI	β_{58}	0.041	0.062
non-VOC/VOI	β_{61}	0.053	0.076
non-VOC/VOI	β_{62}	0.053	0.076
non-VOC/VOI	β_{63}	0.043	0.063
non-VOC/VOI	β_{64}	0.051	0.074
non-VOC/VOI	β_{65}	0.053	0.076
non-VOC/VOI	β_{67}	0.058	0.084
non-VOC/VOI	β_{68}	0.052	0.076
non-VOC/VOI	β_{71}	0.032	0.041
non-VOC/VOI	β_{72}	0.032	0.041
non-VOC/VOI	β_{73}	0.022	0.028
non-VOC/VOI	β_{74}	0.0096	0.012
non-VOC/VOI	β_{75}	0.023	0.029
non-VOC/VOI	β_{76}	0.032	0.042
non-VOC/VOI	β_{78}	0.066	0.085
non-VOC/VOI	β_{81}	0.028	0.036
non-VOC/VOI	β_{82}	0.028	0.036
non-VOC/VOI	β_{83}	0.03	0.038
non-VOC/VOI	β_{84}	0.022	0.028
non-VOC/VOI	β_{85}	0.027	0.034
non-VOC/VOI	β_{86}	0.047	0.06
non-VOC/VOI	β_{87}	0.073	0.093
all	Z_1 (days, same below)	2.9	4
all	Z_2	3.3	4.3
all	Z_3	3.4	4.4
all	Z_4	3.4	4.4
all	Z_5	3.5	4.4
all	Z_6	3.5	4.5
all	Z_7	3.3	4.2
all	Z_8	3.3	4.2
all	D_1	2.1	2.9
all	D_2	2.7	3.6
all	D_3	3.2	4.1
all	D_4	3.4	4.4

all	D_5	3.1	4.1
all	D_6	3.2	4.2
all	D_7	2.8	3.7
all	D_8	2.5	3.3
all	IFR_1	3.10E-05	5.00E-05
all	IFR_2	3.00E-05	4.90E-05
all	IFR_3	3.10E-05	4.90E-05
all	IFR_4	3.00E-05	4.90E-05
all	IFR_5	3.00E-04	0.00048
all	IFR_6	0.0029	0.004
all	IFR_7	0.013	0.016
all	IFR_8	0.046	0.055
all	EDR_1	0.0087	0.013
all	EDR_2	0.0059	0.0084
all	EDR_3	0.0023	0.0033
all	EDR_4	0.0046	0.006
all	EDR_5	0.01	0.012
all	EDR_6	0.019	0.023
all	EDR_7	0.031	0.039
all	EDR_8	0.057	0.07
all	*Infection detection rate, r_1*	0.14	0.19
all	*Infection detection rate, r_2*	0.21	0.26
all	*Infection detection rate, r_3*	0.23	0.29
all	*Infection detection rate, r_4*	0.28	0.34
all	*Infection detection rate, r_5*	0.39	0.47
all	*Infection detection rate, r_6*	0.36	0.42
all	*Infection detection rate, r_7*	0.33	0.41
all	*Infection detection rate, r_8*	0.34	0.41

695
696

Table S3. Estimated IFR for different variants and changes compared to the baseline risk estimated for preexisting variants during Oct – Dec 2020, using Eqn 3.

Age	IFR, baseline (%)	IFR, B.1.526 (%)	Changes, B.1.526 (%)	Model fit, R^2
<25	0.004 (0.0021, 0.0059)	0.004 (0.0038, 0.0041)	-0.03 (-3.8, 3.8)	1
25-44	0.04 (0.021, 0.059)	0.035 (0.031, 0.038)	-12 (-21, -3.1)	0.97
45-64	0.29 (0.15, 0.44)	0.42 (0.24, 0.59)	43 (-17, 100)	0.67
65-74	1 (0.57, 2.5)	1.5 (0.53, 2.5)	46 (-50, 140)	0.46
75+	4.1 (2.2, 6.3)	6.1 (5.1, 7)	47 (25, 69)	0.94
all	0.35 (0.2, 0.58)	0.5 (0.4, 0.61)	43 (13, 73)	0.89

References included in the tables:

1. Yang W, Kandula S, Huynh M, et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. *The Lancet Infectious diseases* 2021; **21**(2): 203-12.

2. New York City Department of Health and Mental Hygiene. NYC DOHMH population estimates, modified from US Census Bureau interpolated intercensal population estimates, 2000-2018. . Updated August 2019. ed.

3. Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. *PLoS Med* 2008; **5**(3): e74.

4. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New Engl J Med* 2020.

5. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020.

6. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* 2020; **368**(6490): 489-93.

7. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet Infectious diseases* 2020.

8. Yang W, Shaman J. A simple modification for improving inference of non-linear dynamical systems. *arXiv* 2014: 1403.6804.

9. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious diseases* 2020.

10. Yang W, Shaman J. Epidemiological characteristics of three SARS-CoV-2 variants of concern and implications for future COVID-19 pandemic outcomes. *medRxiv* 2021: 2021.05.19.21257476.

11. Public Health England. Investigation of novel SARS-CoV-2 variant, Variant of Concern
202012/01, Technical briefing 3, 2020.
12. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody
neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike
protein mutation. *medRxiv* 2021: 2021.03.07.21252647.

Fig S1. Estimated infection-detection rate by age group. Red lines show the estimated median
infection-detection rate with surrounding areas indicating the 50% (darker color) and 95%
(lighter color) CrI. For comparison, the grey bars show the number of cases reported for each
week from the week of Oct 4, 2020 to Apr 25, 2021. Labels of x-axis show the week starts
(mm/dd/yy).

737
738

Fig S2. Model-fit by age group. Boxes show model estimates (thick horizontal lines and box
edges show the median, 25th, and 75th percentiles; vertical lines extending from each box show
95% Crl) and red dots show corresponding.

Fig S3. Estimated cumulative infection rates by age group. Thick horizontal lines and box edges
show the median, 25th, and 75th percentiles; vertical lines extending from each box show 95%
CrI.

746
747
748